Non-Hodgkin Lymphoma | Specialty

Dr. LaCasce Discusses the FDA Approval of Lenalidomide/Rituximab in Non-Hodgkin Lymphoma

May 28th 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the FDA approval of lenalidomide (Revlimid) and rituximab (Rituxan; R2) in non-Hodgkin lymphoma.

FDA Approves Lenalidomide/Rituximab for Indolent Non-Hodgkin Lymphoma

May 28th 2019

The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

Frontline Lenalidomide/R-CHOP Combo Misses Primary Endpoint in DLBCL

April 26th 2019

The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2-CHOP) did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

April 17th 2019

Daratumumab was associated with low overall response rates in patients with relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1

Lenalidomide/Rituximab Data Published as FDA Weighs Non-Hodgkin Lymphoma Approval

April 9th 2019

The R2 regimen of lenalidomide plus rituximab significantly reduced the risk of disease progression or death compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to results from the pivotal phase III AUGMENT trial.

Dr. Shaughnessy Discusses Unanswered Questions in DLBCL

April 4th 2019

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).

Dr. Kaplan on a Study With Combination Immune Macrophage Checkpoint Blockade in Lymphoma

March 6th 2019

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.

Using BTK Inhibitors in Community Practice

March 4th 2019

BTK Combination Strategies for B-Cell Malignancies

March 4th 2019

BTK Inhibitors in Chronic Lymphocytic Leukemia

March 4th 2019

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

March 4th 2019

First-Generation BTK Inhibition in Mantle Cell Lymphoma

March 4th 2019

BTK Inhibitors in Waldenstrom Macroglobulinemia

March 4th 2019

Resistance to BTK Inhibitors in B-Cell Malignancies

March 4th 2019

BTK Inhibitors Explored in B-Cell Malignancies

March 4th 2019

Targeting BTK in B-Cell Malignancies

March 4th 2019

Genomic Profiling in Chronic Lymphocytic Leukemia

March 4th 2019

Diagnosing Waldenstrom Macroglobulinemia

March 4th 2019

Dr. Casulo on Predicting Outcomes in Follicular Lymphoma

March 2nd 2019

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

Dr. Gordon on Chemotherapy-Free Regimens in Follicular Lymphoma

February 28th 2019

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor of medicine (hematology and oncology), Northwestern University Feinberg School of Medicine, discussed emerging chemotherapy-free regimens in the treatment of patients with follicular lymphoma.